Opaleye Management Inc. sold $4.8M of ETON
owner at Eton Pharmaceuticals, Inc.. 126,685 shares at an average of $37.64, traded Jul 2, 2026, filed Jul 7, 2026.
Score components
- +12Role10% owner
- +25Trade size$4.8M at market
- 0Share of holdings soldSold 4.6% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-032394, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | -65,000 | $37.39 | $2.4M | 2,710,000 | Jul 7, 2026 |
| Jul 2, 2026 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Managed Account | -25,000 | $37.39 | $935k | 60,000 | Jul 7, 2026 |
| Jul 6, 2026 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | -10,000 | $38.00 | $380k | 2,700,000 | Jul 7, 2026 |
| Jul 7, 2026 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | -20,000 | $38.37 | $767k | 2,680,000 | Jul 7, 2026 |
| Jul 7, 2026 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Managed Account | -6,685 | $38.37 | $257k | 53,315 | Jul 7, 2026 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $1.6M 25,000 shares | -40% | |
| 65Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $6.1M 100,000 shares | -9% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 45Moderate | ETONsell Eton Pharmaceuticals, Inc. | Jennifer McKie Adams director | $1.6M 50,000 shares | -100% | |
| 63Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.8M 120,000 shares | -13% | |
| 53Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $3.2M 100,000 shares | -147% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.